PROCEPT BioRobotics Corp (PRCT) Stock

PROCEPT BioRobotics Corporation is a surgical robotics company specializing in minimally invasive urologic treatments. The company develops and manufactures the AquaBeam Robotic System and HYDROS Robotic System, which deliver Aquablation therapy—a heat-free, waterjet-based treatment for benign prostatic hyperplasia (BPH). These image-guided, computer-assisted platforms combine real-time multidimensional imaging with personalized treatment planning and automated robotics to precisely remove prostate tissue while preserving sexual function and continence across prostates of all shapes and sizes. The Aquablation therapy approach is clinically proven to provide significant, long-lasting symptom relief. PROCEPT BioRobotics operates through a recurring-revenue business model, generating income from both robotic system sales and consumable handpieces used in procedures. The company serves urologists and patients in the United States and internationally, addressing a substantial market opportunity in men's health and lower urinary tract symptoms. Founded in 2007 and headquartered in San Jose, California, PROCEPT BioRobotics continues to expand its installed base of robotic systems while advancing clinical applications, including investigational studies for localized prostate cancer treatment.